Singapore - English - HSA (Health Sciences Authority)

scanmed technology (s) pte ltd - cardiovascular - the device is intended for use under the direct supervision of a licensed healthcare practitioner. it is a diagnostic device intended to monitor and record electrocardiographic data from the patient during exercise, as well as perform resting ecg analysis. the device is not intended to be used as a vital signs physiological monitor. this device will not cause abnormal operation of the patient's cardiac pacemaker or other electronic stimulator. the device is not intended for use with high-frequency surgical units. disconnect the patient from the device before using a high-frequency surgical unit. the device uses a computerized analysis program which can be used as a tool in ecg interpretation.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - reboxetine mesilate -

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - reboxetine mesilate 2.612mg equivalent to 2 mg reboxetine free base - tablet - 2 mg - active: reboxetine mesilate 2.612mg equivalent to 2 mg reboxetine free base excipient: calcium hydrogen phosphate dihydrate crospovidone hydrated silica magnesium stearate powdered cellulose - reboxetine is indicated for the treatment of depressive illness and for maintaining the clinical improvement in patients initially responding to treatment. the remission of the acute phase of the depressive illness is associated with an improvement in the patient's quality of life in terms of social adaptation.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - reboxetine mesilate 5.224mg equivalent to 4 mg reboxetine free base - tablet - 4 mg - active: reboxetine mesilate 5.224mg equivalent to 4 mg reboxetine free base excipient: calcium hydrogen phosphate dihydrate crospovidone hydrated silica magnesium stearate powdered cellulose

United States - English - NLM (National Library of Medicine)

directrx - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - - carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see warnings and precautions (5)] 1.1 osteoarthritis (oa) celecoxib is indicated for relief of the signs and symptoms of oa [see clinical studies (14.1)] 1.2 rheumatoid arthritis (ra) celecoxib is indicated for relief of the signs and symptoms of ra [see clinical studies (14.2)] 1.3 juvenile rheumatoid arthritis (jra) celecoxib is indicated for relief of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3)] 1.4 ankylosing spondylitis (as) celecoxib is indicated for the relief of signs and symptoms of as [see clinical studies (14.4)] 1.5 acute pain (ap) celecoxib is indicated for the management of ap in adults [see clinical studies (14.5)] 1.6 primary dysmenorrhea (pd) celecoxib is indicated for the treatment of pd [see clinical s

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 50 mg

United States - English - NLM (National Library of Medicine)

cardinal health - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 100 mg - celebrex is indicated for the management of the signs and symptoms of oa [see clinical studies (14.1) ] for the management of the signs and symptoms of ra [see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] for the management of the signs and symptoms of as [see clinical studies (14.4) ] for the management of acute pain in adults [see clinical studies (14.5) ] for the management of primary dysmenorrhea [see clinical studies (14.5) ] celebrex is contraindicated in the following patients: pregnancy category c. pregnancy category d from 30 weeks of gestation onward. risk summary use of nsaids, including celebrex, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including celebrex, in pregnant women starting at 30 weeks of gestation. there are no adequate and well-controlled studies of celebrex in pregnant women. data from observational stu

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 100 mg

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - celebrex is indicated for the management of the signs and symptoms of oa [see clinical studies (14.1) ] for the management of the signs and symptoms of ra [see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] for the management of the signs and symptoms of as [see clinical studies (14.4) ] for the management of acute pain in adults [see clinical studies (14.5) ] for the management of primary dysmenorrhea [see clinical studies (14.5) ] celebrex is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see warnings and precautions (5.7, 5.9) ]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids, have been reported in such patients [see warnings and precautions (5.7, 5.8) ]. - in the setting of

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - celecoxib capsules are  indicated for the management of the signs and symptoms of oa [see clinical studies (14.1) ] for the management of the signs and symptoms of ra [see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] for the management of the signs and symptoms of as [see clinical studies (14.4) ] for the management of acute pain in adults [see clinical studies (14.5) ] for  the   management   of   primary   dysmenorrhea  [see  clinical  studies  (14.5) ] celecoxib capsules are contraindicated in the following patients: pregnancy category c. pregnancy category d from 30 weeks of gestation onward. risk summary use of nsaids, including celecoxib, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including celecoxib, in pregnant women starting at 30 weeks of gestation. there are no adequate and well-controlled studies of celec